Article Details
Retrieved on: 2021-06-15 19:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 Mab) Following Type B FDA Meeting. By.
Article found on: www.digitaljournal.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here